U.S. Minimal Residual Disease Testing Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Minimal Residual Disease Testing Market
- ✓Market Size 2024: USD 1.1 billion
- ✓Market Size 2032: USD 2.9 billion
- ✓CAGR: 12.9%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure MolDX Pathway Now: Diagnostics developers should file for MolDX technical assessment by Q4 2026 for a tumor-informed or flow-based MRD assay, because Medicare coverage determines commercial payer contracts. Labs without a Medicare pathway will lose hospital outreach volume to incumbents before 2028.
MRD Testing in the United States: Market Overview
The United States is the largest and most structurally advanced minimal residual disease (MRD) testing market in the world, valued at USD 1.1 billion in 2024 and forecast to reach USD 2.9 billion by 2032. Unlike the global market, where many countries still rely on flow cytometry in central hospital laboratories, the U.S. market is defined by a fee-for-service laboratory model in which reimbursement follows Medicare coverage decisions. Blood-based and bone-marrow assays are both billed as laboratory services, so commercial traction depends on payer policy as much as clinical evidence.
Market structure is shaped by two regulatory tracks. Adaptive Biotechnologies' clonoSEQ holds FDA clearance for multiple myeloma and B-cell acute lymphoblastic leukemia, giving it a regulated benchmark claim. Most competing assets, including Natera's Signatera and Guardant Health's Reveal, operate as laboratory-developed tests under Clinical Laboratory Improvement Amendments (CLIA) certification administered by the Centers for Medicare and Medicaid Services, so commercial success depends on payer adjudication rather than premarket approval.
Growth Drivers Behind U.S. MRD Testing
Medicare coverage is the primary growth lever. Palmetto GBA's MolDX program, which issues technical assessments for molecular diagnostics on behalf of Medicare Administrative Contractors, has granted coverage to tumor-informed MRD assays for specified cancers. Each favorable determination tends to trigger commercial payer policies, creating a reimbursement cascade that expands addressable volume across hospital outreach and reference laboratory channels.
Pharmaceutical demand is the second driver. In April 2024, the FDA's Oncologic Drugs Advisory Committee endorsed MRD negativity as an accelerated approval endpoint in multiple myeloma, pushing sponsors toward companion testing. Epidemiology supports steady volume growth: the American Cancer Society estimated roughly 35,800 new U.S. multiple myeloma cases in 2024, while NCCN colon cancer guidelines now discuss ctDNA-guided surveillance for patients after curative resection.
Market Restraints and Entry Barriers
Reimbursement volatility is the principal entry barrier. Medicare's Clinical Laboratory Fee Schedule rates are set under market-based pricing rules established by the Protecting Access to Medicare Act of 2014 (PAMA), and repeated congressional delays to PAMA reporting and rate reductions have left laboratories without stable price floors. Commercial payers also apply prior authorization and demand evidence of clinical utility before covering serial MRD testing, extending the time between launch and meaningful revenue.
Regulatory uncertainty and incumbency raise costs further. The FDA's laboratory-developed test final rule was vacated by the U.S. District Court for the Eastern District of Texas in March 2025, which keeps CLIA as the governing standard but leaves future federal oversight unresolved. Reference laboratories such as Quest Diagnostics and Labcorp control payer contracts and hospital outreach networks, so new entrants must displace established ordering relationships to reach volume.
Market Opportunities in the United States
The most concrete near-term opportunity is colorectal cancer MRD, where tumor-informed ctDNA assays guide adjuvant chemotherapy decisions in stage II and III patients. Exact Sciences has commercialized Oncodetect for this indication, and the colorectal segment is projected to exceed USD 400 million in U.S. testing value by 2030 as surveillance guidelines mature. Developers that secure MolDX coverage first will capture the initial wave of commercial payer contracts.
Community oncology is the second opening. The majority of U.S. cancer patients are treated outside academic centers, yet most community practices lack in-house MRD capacity and depend on mail-in blood collection kits. Vendors offering standardized draw logistics, electronic ordering integration with Epic and Oracle Health, and rapid turnaround for multiple myeloma and CLL monitoring can address an estimated USD 250 million community segment by 2030.
Market at a Glance
| Metric | Detail |
|---|---|
| Market Size 2024 | USD 1.1 billion |
| Market Size 2032 | USD 2.9 billion |
| Growth Rate (CAGR) | 12.9% |
| Most Critical Decision Factor | Medicare coverage determination timing and MolDX pathway |
| Largest Region | Northeast and Mid-Atlantic |
| Competitive Structure | Concentrated; top providers and reference laboratories hold majority share |
Leading Market Participants
- Adaptive Biotechnologies
- Natera
- Guardant Health
- Exact Sciences
- NeoGenomics
- Personalis
- Quest Diagnostics
- Labcorp
- Foundation Medicine
- Illumina
Regulatory and Policy Environment
FDA oversight of MRD assays operates under the Federal Food, Drug, and Cosmetic Act, with clearance or approval required for commercial test kits and reagents. Laboratory-developed tests are governed by the Clinical Laboratory Improvement Amendments of 1988, administered by CMS, which requires laboratory certification renewed every two years and proficiency testing for each analyte. Coverage decisions are issued through Palmetto GBA's MolDX program, typically within six to twelve months of technical assessment submission.
Financial policy operates through Medicare Part B clinical laboratory payment rules rather than direct subsidies. PAMA governs Clinical Laboratory Fee Schedule rate setting based on private payer data reporting, and Congress has repeatedly deferred reporting cycles. The FDA's Breakthrough Devices Program offers expedited review for MRD assays demonstrating meaningful advantages over existing options, while the 2025 vacatur of the LDT rule keeps day-to-day oversight with CLIA.
Long-Term Outlook for U.S. MRD Testing
By 2032, the U.S. MRD testing market is projected to reach USD 2.9 billion, with ctDNA-based colorectal and breast assays becoming the fastest-growing share alongside established hematologic franchises. Multiple myeloma and leukemia testing will remain the revenue anchor, supported by MRD endpoints in drug development and widening Medicare coverage. Pricing will compress as competition among tumor-informed assays intensifies, shifting differentiation toward turnaround time and electronic health record integration.
Consolidation will be the structural outcome, with reference laboratories and diagnostics majors acquiring specialized MRD developers to secure payer contracts and hospital relationships. Policy remains the principal swing factor: durable PAMA reform would stabilize pricing, while further rate cuts would pressure smaller laboratories. Companies that secure MolDX coverage before 2028 will lead the market through 2032.
Frequently Asked Questions
Market Segmentation
- NGS-Based Assays
- Tumor-Informed ctDNA Assays
- Multiparameter Flow Cytometry
- PCR-Based Assays
- Multiple Myeloma
- Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia
- Colorectal Cancer
- Independent Reference Laboratories
- Hospital Outreach Laboratories
- Academic Cancer Centers
- Pharmaceutical Companion Diagnostic Partners
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.